Secure base, several live doors: core not in question, multiple distinct expansion avenues already producing
The model's full reasoning — Q3 2018 call → NOWe need answer YES/NO based on transcript. Need assess both halves. Core business: Agios has TIBSOVO launch in AML, IDHIFA. On call, management discusses launch progress, sales $4.5M, positive. Core is established? They have two IDH inhibitors for AML. They treat as solid. No defending weakness. So base not in question. Additional avenues: Need at least two distinct avenues already real with early results. Let's identify. - TIBSOVO in newly diagnosed AML not eligible for standard therapies: sNDA planned, data from cohort with CR+CRh 41%. This is expansion of indication for existing drug. Already in motion? They have data, regulatory submission planned. Is that "already real and producing at least early results today"? It's clinical data, not revenue. But avenue is expansion of scope with existing product to new patient population. It is already in motion with data. However question says "each avenue counted must be described as ALREADY IN MOTION WITH SOMETHING REAL TO SHOW NOW — actual current revenue, orders, customers, volumes, deployments, openings, or usage in the recent period, however early or small — not merely a plan, pipeline, ambition, or market-size claim." Clinical trial data? It's results, but not commercial. The avenue is regulatory approval for new indication. Is that "already real and producing at least early results today"? They have data from cohort. But "producing" could mean clinical results. Need be careful. - Solid tumors: cholangiocarcinoma Phase 3 CLARITY enrolling, completion first-half 2019. Not yet results? It's ongoing trial, no revenue. Not "already real" in terms of results? They have Phase 1 data? They mention ivosidenib has potential first targeted therapy. But not yet approved. This is pipeline. - Glioma: AG-881, perioperative window study, Phase 1 data. Not commercial. - Mitapivat in pyruvate kinase deficiency: pivotal trials enrolling, expected complete enrollment 2019. Not yet results? They have Phase 2 data? They are conducting patient identification. Not commercial. - Thalassemia: Phase 2 proof-of-concept to initiate by end of year. Not yet. - AG-270 MAT2A inhibitor: Phase 1 dose-escalation, seeing PD effects. Not commercial. - AG-636 DHODH inhibitor: IND submitted. Not yet. - TIBSOVO launch itself is core? The core business is IDH inhibitors in AML.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| LINC | Lincoln Educational Services Corporation | Q1 2024 | 2024-05-06 | B+ |
| ROCK | Gibraltar Industries, Inc. | Q1 2024 | 2024-05-01 | B+ |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| SNV | Synovus Financial Corp. | Q1 2024 | 2024-04-18 | B |
| NICE | NICE Ltd. | Q4 2023 | 2024-02-22 | B+ |
| MET | MetLife, Inc. | Q4 2023 | 2024-02-01 | B+ |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| CPRT | Copart, Inc. | Q1 2024 | 2023-11-16 | B+ |
| FSBC | Five Star Bancorp | Q3 2023 | 2023-10-31 | B |
| ANGO | AngioDynamics, Inc. | Q1 2024 | 2023-10-04 | B |
| OXM | Oxford Industries, Inc. | Q2 2023 | 2023-08-31 | C |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| PERI | Perion Network Ltd. | Q2 2023 | 2023-08-02 | A |
| DAL | Delta Air Lines, Inc. | Q2 2023 | 2023-07-13 | A |
| PFIE | Profire Energy, Inc. | Q1 2023 | 2023-05-13 | B |
| SLF | Sun Life Financial Inc. | Q1 2023 | 2023-05-12 | B |
| CALX | Calix, Inc. | Q1 2023 | 2023-04-20 | C+ |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| M | Macy's, Inc. | Q4 2022 | 2023-03-02 | D |
| POOL | Pool Corporation | Q4 2022 | 2023-02-16 | C+ |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| HIW | Highwoods Properties, Inc. | Q4 2022 | 2023-02-08 | B |
| ADM | Archer-Daniels-Midland Company | Q4 2022 | 2023-01-26 | C+ |
| HBAN | Huntington Bancshares Incorporated | Q4 2022 | 2023-01-20 | B |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| IT | Gartner, Inc. | Q2 2022 | 2022-08-02 | A |
| UPWK | Upwork Inc. | Q2 2022 | 2022-07-27 | C+ |
| SE | Sea Limited | Q1 2022 | 2022-05-17 | F |
| FLYW | Flywire Corporation | Q1 2022 | 2022-05-14 | B+ |
| ZVIA | Zevia PBC | Q1 2022 | 2022-05-12 | B |
| CCRN | Cross Country Healthcare, Inc. | Q1 2022 | 2022-05-04 | B |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| CNXC | Concentrix Corporation | Q1 2022 | 2022-03-30 | B |
| SOPH | SOPHiA GENETICS SA | Q4 2021 | 2022-03-15 | C |
| RELY | Remitly Global, Inc. | Q4 2021 | 2022-03-02 | B |
| RNW | ReNew Energy Global Plc | Q2 2022 | 2021-11-18 | C |
| LOW | Lowe's Companies, Inc. | Q3 2021 | 2021-11-17 | B+ |
| KTB | Kontoor Brands, Inc. | Q3 2021 | 2021-11-04 | A |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| TENB | Tenable Holdings, Inc. | Q2 2021 | 2021-07-27 | A |
| DGX | Quest Diagnostics Incorporated | Q2 2021 | 2021-07-22 | B+ |
| CMTL | Comtech Telecommunications Corp. | Q1 2019 | 2018-12-07 | B+ |
| OGE | OGE Energy Corp. | Q3 2018 | 2018-11-08 | A |
| UMH | UMH Properties, Inc. | Q3 2018 | 2018-11-02 | C+ |
| SRDX | Surmodics, Inc. | Q3 2018 | 2018-08-06 | A |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| ORAN | Orange SA | Q2 2018 | 2018-07-26 | B |
| CP | Canadian Pacific Railway Limited | Q2 2018 | 2018-07-19 | B+ |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| HPE | Hewlett Packard Enterprise Company | Q2 2018 | 2018-05-22 | B+ |
| NOVT | Novanta Inc. | Q4 2017 | 2018-05-12 | B+ |
| SATS | EchoStar Corporation | Q1 2018 | 2018-05-10 | C+ |
| ALLY | Ally Financial Inc. | Q1 2018 | 2018-04-26 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| TOUR | Tuniu Corporation | Q4 2017 | 2018-03-14 | D |
| UPLD | Upland Software, Inc. | Q4 2017 | 2018-03-08 | C+ |
| UNH | UnitedHealth Group Incorporated | Q4 2017 | 2018-01-16 | A |
| ROK | Rockwell Automation, Inc. | Q4 2017 | 2017-11-08 | C |
| HSTM | HealthStream, Inc. | Q3 2017 | 2017-10-24 | C |
| IBTX | Independent Bank Group, Inc. | Q3 2017 | 2017-10-24 | A |
| SNA | Snap-on Incorporated | Q3 2017 | 2017-10-19 | B |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| BCE | BCE Inc. | Q2 2017 | 2017-08-05 | B+ |
| LEA | Lear Corporation | Q2 2017 | 2017-07-26 | B+ |
| CNS | Cohen & Steers, Inc. | Q2 2017 | 2017-07-20 | B |
| ICFI | ICF International, Inc. | Q1 2017 | 2017-05-06 | B+ |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
| SHOO | Steven Madden, Ltd. | Q1 2017 | 2017-04-21 | C |
| DHR | Danaher Corporation | Q1 2017 | 2017-04-20 | B |
| SXT | Sensient Technologies Corporation | Q4 2016 | 2017-02-10 | A |
| BDC | Belden Inc. | Q4 2016 | 2017-02-02 | B |
| BC | Brunswick Corporation | Q3 2016 | 2016-10-28 | B+ |
| NDSN | Nordson Corporation | Q3 2016 | 2016-08-23 | A |
| VRNS | Varonis Systems, Inc. | Q2 2016 | 2016-08-09 | B+ |
| CHDN | Churchill Downs Incorporated | Q2 2016 | 2016-08-04 | C+ |
| GEO | The GEO Group, Inc. | Q2 2016 | 2016-08-02 | B+ |
| THRM | Gentherm Incorporated | Q2 2016 | 2016-07-28 | C+ |
| TRV | The Travelers Companies, Inc. | Q2 2016 | 2016-07-21 | C+ |
| LBTYK | Liberty Global's | Q1 2016 | 2016-05-10 | C+ |
| ESE | ESCO Technologies Inc. | Q2 2016 | 2016-05-03 | A |
| INGR | Ingredion Incorporated | Q1 2016 | 2016-05-01 | B+ |
| RCL | Royal Caribbean Cruises Ltd. | Q1 2016 | 2016-04-29 | C+ |
| FFBC | First Financial Bancorp. | Q1 2016 | 2016-04-22 | B |
| CAL | Caleres, Inc. | Q4 2015 | 2016-03-15 | C+ |
| WK | Workiva Inc. | Q4 2015 | 2016-03-01 | B |
| HPP | Hudson Pacific Properties, Inc. | Q4 2015 | 2016-02-25 | C |
| HD | The Home Depot, Inc. | Q4 2015 | 2016-02-23 | A |
| ENLC | EnLink Midstream, LLC | Q4 2015 | 2016-02-17 | C+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
SOPH · Q4 2021 → YESThe question is: Does management speak from a SECURE, SETTLED CORE BUSINESS while ALSO describing MORE THAN ONE distinct avenue of additional growth beyond that core, where EACH avenue is already real...YES The transcript shows a settled core business delivering 42% revenue growth, 142% NDR, low churn, and rising utilization (66k analyses, 382 recurring customers). Beyond this, management describes at least two distinct additional avenues already producing early results: (1) new product innovation (HRD solution 100% launched with SOFIVA GENOMICS validation underway, AstraZeneca partnership, patents, and clear demand; CarePath in active DEEP-Lung-IV study with 16 sites activated and hundreds of patients enrolled), and (2) biopharma expansion (Peter Casasanto hired, HRD solution with AZ, 18–20 large pharma conversations underway, and GE partnership with commercial lead-sharing traction). These are presented as meaningful, real-world expansions with current deployments and usage, not mere plans. The call treats the core as solid ground while highlighting these separate growth vectors as already in motion. No single avenue or aspirational language applies. 2022 guide and US/reference-lab momentum are framed as extensions of these proven directions. Thus the posture meets both required halves. 2022 guide and US/reference-lab momentum are framed as extensions of these proven directions. Thus the posture meets both required halves.
RELY · Q4 2021 → YESThe question is: Does management speak from a SECURE, SETTLED CORE BUSINESS — one it is plainly not defending, fixing, or fighting to keep — while ALSO describing MORE THAN ONE distinct avenue of addi...YES The transcript shows a settled core remittance business delivering strong growth (50% active customer increase, 78% revenue growth, >90% retention, 6x LTV/CAC) with no defense or repair needed. Beyond that, management explicitly describes two distinct additional avenues already producing results: (1) 2021 non-US revenue of $120 million (26% of total, up from $58 million) from corridor expansion (700+ new corridors added, total >2,100), and (2) new products/services outside remittances, including the launched Coinbase partnership and ongoing rollout of Remitly for developers (new customers and pipeline already in motion). These are presented as real, current parts of the growth story with early traction, separate from core remittance improvements. The third driver (reinvesting in remittance experience) is treated as core, not additional. This meets the criteria for both halves of the posture. No other transcript elements contradict this reading. The answer is therefore YES. (The question requires reporting YES or NO only.) The posture is conveyed directly by management in its own words. The answer is therefore YES. (The question requires reporting YES or NO only.
ALLY · Q1 2018 → YESThe question is: Does management speak from a SECURE, SETTLED CORE BUSINESS — one it is plainly not defending, fixing, or fighting to keep — while ALSO describing MORE THAN ONE distinct avenue of addi...YES The transcript shows a secure core in auto finance (originations up 7%, used mix >50%, portfolio yield up and loss rate down, credit benign) and retail deposits ($3.7B growth, record Q1, customer growth 59k, retention >90%). Management treats these as solid, 2018-outlook-tracking performance without defending weakness. Beyond the core, two distinct avenues already producing early results: - Ally Invest: “making good progress” with “improved customer interface and technology” rolling out this year. - Ally Home / mortgage finance: “expect us to make a lot of great progress” while 2018 net financing revenue is already up YoY and portfolio growth is occurring; corporate finance adds a third with 25% YoY loan growth and new specialized verticals. These are presented as real, in-motion expansions (not plans or pilots) that management is actively scaling, separate from the core auto/deposit business and already visible in current segment results. The call is not about rescuing or explaining the core; it is about leveraging it while adding these new avenues today. The posture therefore meets both required halves. NO.